Effect of maximum dose of atorvastatin on inflammation, thrombogenesis and fibrinolysis in high-risk patients with ischemic heart disease;Efecto de dosis máximas de atorvastatina en la inflamación, la trombogénesis y la función fibrinolítica en pacientes con cardiopatía isquémica de alto riesgo

Revista Espanola de Cardiologia

Volumn 58, Issue 8, 2005, Pages 934-940

  Tello, Antonio ^a   Marín, Francisco ^a   Roldán, Vanessa ^b   García Herola, Ana ^b   Lorenzo, Sofía ^a   Climent, Vicente E ^a   de Teresa, Luis ^b   Sogorb, Francisco ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Hospital de San Vicente   (Spain)

Author keywords

C reactive protein; Fibrinolysis; Hypercholesterolemia; Thrombosis

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; MAXIMUM PERMISSIBLE DOSE; THROMBOGENESIS;

EID: 26444514521     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078130     Document Type: Article

References (42)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
2. Shepherd J, Cobe SM, Ford I, Isles CJ, Lorimer AR, Mcfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9.
4. Downs GR, Clearfield M, Weiss S, Whithney E, Shaphiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TEXCAPS. JAMA. 1998;279:1615-22.
5. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomized placebo controlled trial. Lancet. 2002:360:7-22.
6. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
7. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-9.
8. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effectes of statins: Lipid reduction and beyond. J Clin Endocrinol Metab. 2002;87:1451-8.
9. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.
10. Angiolillo DJ, Biasucci LM, Liuzzo G, Crea F. La inflamación en los síndromes coronarios agudos: mecanismos e implicaciones clínicas. Rev Esp Cardiol. 2004;57:433-46.
11. Levi M, Van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698-704.
12. Schwartz GG, Olsson Ag, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized contolled trial. JAMA. 2001;285:1711-8.
13. Serruys PWJC, De Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. JAMA. 2002;287:3215-22.
14. Colivicchi F, Guido V, Tubaro M, Ammirati F, Montefoschi N, Varveri A, et al. Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q wave myocardial infarction. Am J Cardiol. 2002;90:872-4.
15. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386-91.
16. Serrano M, Madoz E, Ezpeleta I, San Julián B, Amézqueta C, Pérez Marco JA, et al. Abandono del tabaco y riesgo de nuevo infarto en pacientes coronarios: estudio de casos y controles anidado. Rev Esp Cardiol. 2003;56:436-7.
17. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statins therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.
18. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
19. Gonzálvez M, Ruiz Ros JA, Pérez Paredes M, Lozano ML, Jiménez DM, Martínez Corbalán F, et al. Efecto de la administración precoz de pravastatina en los valores de proteína C reactiva y de interleucina 6 en la fase aguda del infarto de miocardio con elevación del segmento ST. Rev Esp Cardiol. 2004;57:916-23.
20. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107: 363-9.
21. Bodí V, Sanchís J, Llácer A, Facila L, Nuñez J, Pellicer M, et al. Valor independiente de la proteína C reactiva para predecir acontecimientos mayores al primer mes y al año en los síndromes coronarios agudos sin elevación del ST. Med Clin (Barc). 2004; 122:248-52.
22. Lee KW, Lip GYH. Acute coronary syndromes: Virchow's triad revisited. Blood Coagul Fibrinolysis. 2003; 14:605-25.
23. DiGarbo V, Cordova R, Avellone G. Increased thrombin formation and complement activation in patients with type IIA hyperlipoproteinemia: effects of simvastatin treatment. Curr Therapeut Res. 1997;58:706-23.
24. Szczeklik A, Musial J, Undas A, Gajewski P, Góra P, Swadzba J, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol. 1999;33:1286-93.
25. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 2000;85:47-51.
26. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscl Thromb Vasc Biol. 1997;17:265-72.
27. Jansson JH, Johansson B, Boman K, Nilsson TK. Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med. 1991;229:309-16.
28. Poli K, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, et al. Association of blood pressure and fibrinolytic potential in the Framingham Offspring Study. Circulation. 2000;101:264-9.
29. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van der Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-41.
30. Marín F, Roldán V, Lip GYH. Fibrinolytic function in atrial fibrillation. Thromb Res. 2003;109:233-40.
31. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and systemic hemostatic profile. J Am Coll Cardiol. 1999;33:1294-304.
32. Tekin A, Tekin G, Güzelsoy D, Kaya A, Gürel ÇV, Yigit Z, et al. Effects of Atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipemic patients with angiographically proven coronary artery disease. Am J Cardiol. 2004;93:206-9.
33. Bruni F, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Cercigani M, et al. Effect of atorvastatin on different fibrinolysis mechanisms in hypercholesterolemic subjects. Int J Cardiol. 2004;95:269-74.
34. Kent SM, Taylor AJ. Usefulness of lowering low-density lipoprotein cholesterol to < 70 mg/dL and usefulness of C-reactive protein in patient selection. Am J Cardiol. 2003;92:1224-7.
35. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomised controlled trial. JAMA. 2004;291:1071-80.
36. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.
37. Grundy SM, Cleeman JI, Merz NB, Brewer B, Clark LY, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
38. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8.
39. Nissen SE, Tuzcu EM Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
40. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004;110:1406-12.
41. Llevadot J, Asahara T. Efecto de las estatinas en la inducción de angiogénesis y vasculogénesis. Rev Esp Cardiol. 2002;55:838-44.
42. Tuñón J, Egido J. Disfunción endotelial, inflamación y estatinas: nuevas evidencias. Rev Esp Cardiol. 2004;57:903-5.